News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Revamped Radius Looks To Cash In With $86 Million IPO



2/27/2014 7:18:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Radius Health has raised more than $250 million from private investors to develop an osteoporosis drug to pit against Eli Lilly’s teriparatide (Forteo). Now, after switching CEOs three times and kicking off a big Phase III trial, the Cambridge, MA-based company will see if it can get the same type of financial support on Wall Street. Radius has become the latest local biotech to file for an IPO.

Help employers find you! Check out all the jobs and post your resume.

Read at Xconomy
Read at Nasdaq


comments powered by Disqus
Xconomy
Nasdaq
Radius
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES